These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34421416)

  • 1. Liver, Renal, and Cardiovascular Failure After Unintentional Overdose of Tizanidine in a 2-Year-Old Child.
    Vila J; Morgenstern A; Vendrell L; Ortega J; Danés I
    J Pediatr Pharmacol Ther; 2021; 26(6):643-646. PubMed ID: 34421416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.
    Henney HR; Chez M
    Paediatr Drugs; 2009; 11(6):397-406. PubMed ID: 19877725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Use of Clonidine Patch to Treat Tizanidine Withdrawal.
    Deutsch AB; Hartman CF; Flaherty CP; Ebeling-Koning NE; Beauchamp GA; Katz KD
    Cureus; 2024 Feb; 16(2):e54831. PubMed ID: 38529428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric tizanidine toxicity reversed with naloxone: a case report.
    Bader D; Adam A; Shaban M; Alyahya B
    Int J Emerg Med; 2021 Dec; 14(1):73. PubMed ID: 34906071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
    Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
    Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
    Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
    Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
    Wagstaff AJ; Bryson HM
    Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
    Vakhapova V; Auriel E; Karni A
    Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy.
    Publow SW; Branam DL
    Am J Health Syst Pharm; 2010 Oct; 67(19):1606-10. PubMed ID: 20852161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
    Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K
    Arch Neurol; 1997 Jun; 54(6):731-6. PubMed ID: 9193208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tizanidine Induced Hypotension: Report of a Case and Review of the Literature.
    Mahajan R; Kalita J
    Curr Drug Saf; 2024; 19(2):313-316. PubMed ID: 37489780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
    Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
    Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia].
    Tanaka H; Fukuda I; Miyamoto A; Oka R; Cho K; Fujieda K
    No To Hattatsu; 2004 Nov; 36(6):455-60. PubMed ID: 15560387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified release tizanidine: a review.
    Hutchinson DR
    J Int Med Res; 1989; 17(6):565-73. PubMed ID: 2697626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
    Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
    J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
    Johnson TR; Tobias JD
    J Child Neurol; 2000 Dec; 15(12):818-9. PubMed ID: 11198499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonidine Compounding Error: Bradycardia and Sedation in a Pediatric Patient.
    Barbuto AF; Burns MM
    J Emerg Med; 2020 Jul; 59(1):53-55. PubMed ID: 32389431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sedative and sympatholytic effects of oral tizanidine in healthy volunteers.
    Miettinen TJ; Kanto JH; Salonen MA; Scheinin M
    Anesth Analg; 1996 Apr; 82(4):817-20. PubMed ID: 8615503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.